Northfield Files BLA For Blood Substitute, Seeks Capital Infusion
Executive Summary
Northfield Laboratories hopes to translate enthusiasm on Wall Street for the first BLA submission for a blood substitute into at least $40 mil. of additional capital to help commercialize PolyHeme.
You may also be interested in...
Northfield Labs PolyHeme Blood Substitute May See FDA Action By Feb 2002
Northfield Laboratories hopes for action on its BLA for the human-derived hemoglobin substitute PolyHeme by February 2002.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials